SlidesetHIV19th INTEREST 2025Abstract #4 Determinants of Education Institution Enrolment Among Orphaned and Vulnerable Children (OVC) in Namibia: Findings From the Project HOPE Namibia OVC Program - Hadrian MangwanaView Slideset
SlidesetHIV19th INTEREST 2025Abstract #28 Perceptions of Changes in Risk Factors and Adherence as a Result of Engaging in a Packaged Intervention During the Early ART Initiation Period - Catherine OrrellView Slideset
SlidesetHIV19th INTEREST 2025Abstract #27 Advanced HIV Disease Diagnosis and Other Predictors of Treatment Outcomes Among Newly Diagnosed People Living with HIV in Oyo State, Nigeria - Dickson AdetoyeView Slideset
SlidesetHIV19th INTEREST 2025Abstract # 26 Early Programmatic Outcomes of 512 Self-Reported Art-Naïve People in the Era of Dolutegravir-Based Regimens - Catherine OrrellView Slideset
SlidesetHIV19th INTEREST 2025Abstract # 24 Improvement in Drug Concentrations After an Adherence Intervention: Data From the RETAIN Study - Catherine OrrellView Slideset
NRNatella RakhmaninaMD, PhD, FAAP, FCP, AAHIVSSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025The Long-Acting Anti-Infective Agents for Children and Adolescents Are We Nearly There Yet - Natella RakhmaninaView Slideset
KSRKellie Schoolar ReynoldsPharmDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Regulatory Considerations for Long-Acting Anti-Infectives Challenges and Opportunities - Kellie Schoolar ReynoldsView Slideset
DKDaniel KuritzkesMDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Therapies for Emerging Infections Insights from COVID-19 - Daniel KuritzkesView Slideset
CFCharles FlexnerMDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Anti-Infectives Where Do We Stand - Charles FlexnerView Slideset
FVFrançois VenterMD, FCP, PhDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Anti-Infectives in Resource-Limited Settings - François VenterView Slideset
KSKimberly ScarsiPharmD, MS, FCCPSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Clinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis - Kimberly ScarsiView Slideset
GTGrant TheronBSc, MSc, PhDSlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Recent Developments in TB Testing and Screening Technologies, Including for HIV-associated TB and TB in Children - Grant Theron - SlidesetView Slideset
